Japanese Study Reveals Limitations of Alzheimer’s Drug Lecanemab

Research conducted by scientists at Osaka Metropolitan University in Japan has revealed that lecanemab, a drug designed to eliminate amyloid plaques associated with Alzheimer’s disease, does not improve the brain’s waste clearance system in the short term. This finding raises questions about the effectiveness of targeting amyloid alone in the treatment of Alzheimer’s, indicating a need for a more comprehensive approach to therapy.

The study, led by graduate student Tatsushi Oura and Dr. Hiroyuki Tatekawa, assessed the impact of lecanemab on the glymphatic system—responsible for clearing metabolic waste from the brain. Despite the drug’s ability to reduce the accumulation of amyloid-β (Aβ), researchers found no significant improvement in the glymphatic system three months after treatment. This suggests that nerve damage and impaired waste clearance may occur early in the disease and are challenging to reverse.

Understanding Alzheimer’s Complexity

Alzheimer’s disease is recognized as the most prevalent neurodegenerative disorder, characterized by a multifactorial nature that complicates treatment efforts. The buildup of amyloid-β is a primary contributor to nerve cell damage, but the disease’s progression is influenced by various overlapping factors. Healthy brains utilize the glymphatic system to circulate cerebrospinal fluid, which aids in the removal of metabolic waste. In Alzheimer’s patients, amyloid-β accumulation causes arteries to stiffen, inhibiting fluid flow and disrupting the brain’s waste clearance capabilities.

Lecanemab, recently approved as an antibody therapy, aims to mitigate amyloid-β levels. To evaluate its effects, the research team employed a specialized imaging technique known as the DTI-ALPS index, which tracks changes in the glymphatic system.

Implications of the Findings

Despite expectations that lecanemab would lead to improvements in brain function, the results indicated no marked difference in the DTI-ALPS index from pre-treatment to three months post-therapy. The researchers concluded that while anti-amyloid drugs may slow cognitive decline, they are insufficient for restoring brain function. By the time Alzheimer’s symptoms manifest, neuronal damage and waste clearance impairments are likely already established, underscoring the need for therapies that target multiple biological pathways.

Oura emphasized the importance of understanding why the glymphatic system does not recover following treatment. He stated, “Even when Aβ is reduced by lecanemab, impairment of the glymphatic system may not recover within the short-term.” Future research will examine factors such as age, disease stage, and the extent of white matter lesions to better comprehend the relationship between glymphatic changes and treatment outcomes.

This research was published in the Journal of Magnetic Resonance Imaging. The findings contribute to the growing body of evidence that calls for a multifaceted approach to Alzheimer’s treatment, one that addresses the intricate biological mechanisms at play in this complex disease.